NCT05027932View on ClinicalTrials.gov

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

February 25, 2025

Conditions
Influenza
Interventions
OTHER

IN Placebo

The placebo is normal saline in two syringes administered IN.

OTHER

IM Placebo

The placebo is normal saline in a syringe administered IM.

DRUG

BPL-1357

BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It is administered either IM or IN depending on the assigned treatment group.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH